Comparison of the efficacy of ciclesonide with that of budesonide in mild to moderate asthma patients after step-down therapy: A randomised parallel-group study

Kuo Chin Chiu; Yen Li Chou; Jeng Yuan Hsu; Ming Shian Lin; Ching Hsiung Lin; Pai Chien Chou; Chun Liang Chou; Chun Hua Wang; Han Pin Kuo

doi:10.1038/npjpcrm.2014.10

Comparison of the efficacy of ciclesonide with that of budesonide in mild to moderate asthma patients after step-down therapy: A randomised parallel-group study

Kuo Chin Chiu, Yen Li Chou, Jeng Yuan Hsu, Ming Shian Lin, Ching Hsiung Lin, Pai Chien Chou, Chun Liang Chou, Chun Hua Wang, Han Pin Kuo

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Abstract

BACKGROUND: Inhaled corticosteroids (ICSs) are widely used in asthma control. Ciclesonide (CIC) is an ICS with on-site lung activation for potent anti-inflammatory activity. AIMS: This study aimed to compare the clinical benefit of CIC with budesonide (BUD) in step-down therapy. METHODS: A total of 150 patients with mild-to-moderate asthma well controlled by a combination of ICS and long-acting β₂-agonist were randomised to receive either CIC 320 μg (n = 75) once daily or 2 inhalations of BUD 200 μg (n = 75) twice daily for 12 weeks. The forced expiratory volume in 1 s (FEV₁), maximum mid-expiratory flow (MMEF) and asthma control test (ACT) scores were measured. Ranked stratification of patients and physicians was assessed. RESULTS: Drug adherence was significantly higher in the CIC group than in the BUD group (76.0% vs. 58.7%, P = 0.03). The FEV₁ and MMEF remained stable throughout the 12-week CIC treatment. In the BUD group, FEV₁ significantly decreased at weeks 4 and 12. MMEF had a higher value in the CIC group than in the BUD group. Both patients and physicians ranked CIC over BUD. CONCLUSIONS: CIC is more effective and has better drug adherence than BUD as step-down treatment when asthma is well controlled by combination therapy.

Original language	English
Article number	14010
Journal	npj Primary Care Respiratory Medicine
Volume	24
DOIs	https://doi.org/10.1038/npjpcrm.2014.10
Publication status	Published - May 20 2014
Externally published	Yes

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine
Public Health, Environmental and Occupational Health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/npjpcrm.2014.10

Cite this

Chiu, K. C., Chou, Y. L., Hsu, J. Y., Lin, M. S., Lin, C. H., Chou, P. C., Chou, C. L., Wang, C. H., & Kuo, H. P. (2014). Comparison of the efficacy of ciclesonide with that of budesonide in mild to moderate asthma patients after step-down therapy: A randomised parallel-group study. npj Primary Care Respiratory Medicine, 24, [14010]. https://doi.org/10.1038/npjpcrm.2014.10

@article{1de9c32b07bd478abdfd539cb92557ac,

title = "Comparison of the efficacy of ciclesonide with that of budesonide in mild to moderate asthma patients after step-down therapy: A randomised parallel-group study",

abstract = "BACKGROUND: Inhaled corticosteroids (ICSs) are widely used in asthma control. Ciclesonide (CIC) is an ICS with on-site lung activation for potent anti-inflammatory activity. AIMS: This study aimed to compare the clinical benefit of CIC with budesonide (BUD) in step-down therapy. METHODS: A total of 150 patients with mild-to-moderate asthma well controlled by a combination of ICS and long-acting β2-agonist were randomised to receive either CIC 320 μg (n = 75) once daily or 2 inhalations of BUD 200 μg (n = 75) twice daily for 12 weeks. The forced expiratory volume in 1 s (FEV1), maximum mid-expiratory flow (MMEF) and asthma control test (ACT) scores were measured. Ranked stratification of patients and physicians was assessed. RESULTS: Drug adherence was significantly higher in the CIC group than in the BUD group (76.0% vs. 58.7%, P = 0.03). The FEV1 and MMEF remained stable throughout the 12-week CIC treatment. In the BUD group, FEV1 significantly decreased at weeks 4 and 12. MMEF had a higher value in the CIC group than in the BUD group. Both patients and physicians ranked CIC over BUD. CONCLUSIONS: CIC is more effective and has better drug adherence than BUD as step-down treatment when asthma is well controlled by combination therapy.",

author = "Chiu, {Kuo Chin} and Chou, {Yen Li} and Hsu, {Jeng Yuan} and Lin, {Ming Shian} and Lin, {Ching Hsiung} and Chou, {Pai Chien} and Chou, {Chun Liang} and Wang, {Chun Hua} and Kuo, {Han Pin}",

note = "Funding Information: The authors gratefully acknowledge financial support from a Chang Gung Memorial Hospital Research Project Grant and from Holling Bio-Pharma Corp. Funding Information: This study was supported by Chang Gung Memorial Hospital Research Project Grant, XMRPG380441–2. The funding is sponsored by Holling Bio-Pharma Corp., a Taiwan local agency of ciclesonide, and went through the Chang Gung Memorial Hospital.",

year = "2014",

month = may,

day = "20",

doi = "10.1038/npjpcrm.2014.10",

language = "English",

volume = "24",

journal = "npj Primary Care Respiratory Medicine",

issn = "2055-1010",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Comparison of the efficacy of ciclesonide with that of budesonide in mild to moderate asthma patients after step-down therapy

T2 - A randomised parallel-group study

AU - Chiu, Kuo Chin

AU - Chou, Yen Li

AU - Hsu, Jeng Yuan

AU - Lin, Ming Shian

AU - Lin, Ching Hsiung

AU - Chou, Pai Chien

AU - Chou, Chun Liang

AU - Wang, Chun Hua

AU - Kuo, Han Pin

N1 - Funding Information: The authors gratefully acknowledge financial support from a Chang Gung Memorial Hospital Research Project Grant and from Holling Bio-Pharma Corp. Funding Information: This study was supported by Chang Gung Memorial Hospital Research Project Grant, XMRPG380441–2. The funding is sponsored by Holling Bio-Pharma Corp., a Taiwan local agency of ciclesonide, and went through the Chang Gung Memorial Hospital.

PY - 2014/5/20

Y1 - 2014/5/20

N2 - BACKGROUND: Inhaled corticosteroids (ICSs) are widely used in asthma control. Ciclesonide (CIC) is an ICS with on-site lung activation for potent anti-inflammatory activity. AIMS: This study aimed to compare the clinical benefit of CIC with budesonide (BUD) in step-down therapy. METHODS: A total of 150 patients with mild-to-moderate asthma well controlled by a combination of ICS and long-acting β2-agonist were randomised to receive either CIC 320 μg (n = 75) once daily or 2 inhalations of BUD 200 μg (n = 75) twice daily for 12 weeks. The forced expiratory volume in 1 s (FEV1), maximum mid-expiratory flow (MMEF) and asthma control test (ACT) scores were measured. Ranked stratification of patients and physicians was assessed. RESULTS: Drug adherence was significantly higher in the CIC group than in the BUD group (76.0% vs. 58.7%, P = 0.03). The FEV1 and MMEF remained stable throughout the 12-week CIC treatment. In the BUD group, FEV1 significantly decreased at weeks 4 and 12. MMEF had a higher value in the CIC group than in the BUD group. Both patients and physicians ranked CIC over BUD. CONCLUSIONS: CIC is more effective and has better drug adherence than BUD as step-down treatment when asthma is well controlled by combination therapy.

AB - BACKGROUND: Inhaled corticosteroids (ICSs) are widely used in asthma control. Ciclesonide (CIC) is an ICS with on-site lung activation for potent anti-inflammatory activity. AIMS: This study aimed to compare the clinical benefit of CIC with budesonide (BUD) in step-down therapy. METHODS: A total of 150 patients with mild-to-moderate asthma well controlled by a combination of ICS and long-acting β2-agonist were randomised to receive either CIC 320 μg (n = 75) once daily or 2 inhalations of BUD 200 μg (n = 75) twice daily for 12 weeks. The forced expiratory volume in 1 s (FEV1), maximum mid-expiratory flow (MMEF) and asthma control test (ACT) scores were measured. Ranked stratification of patients and physicians was assessed. RESULTS: Drug adherence was significantly higher in the CIC group than in the BUD group (76.0% vs. 58.7%, P = 0.03). The FEV1 and MMEF remained stable throughout the 12-week CIC treatment. In the BUD group, FEV1 significantly decreased at weeks 4 and 12. MMEF had a higher value in the CIC group than in the BUD group. Both patients and physicians ranked CIC over BUD. CONCLUSIONS: CIC is more effective and has better drug adherence than BUD as step-down treatment when asthma is well controlled by combination therapy.

UR - http://www.scopus.com/inward/record.url?scp=84904396631&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904396631&partnerID=8YFLogxK

U2 - 10.1038/npjpcrm.2014.10

DO - 10.1038/npjpcrm.2014.10

M3 - Article

C2 - 24841163

AN - SCOPUS:84904396631

SN - 2055-1010

VL - 24

JO - npj Primary Care Respiratory Medicine

JF - npj Primary Care Respiratory Medicine

M1 - 14010

ER -

Comparison of the efficacy of ciclesonide with that of budesonide in mild to moderate asthma patients after step-down therapy: A randomised parallel-group study

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this